Aptevo Therapeutics - APVO Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $13.00
  • Forecasted Upside: 295.14 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.29
▲ +0.04 (1.23%)

This chart shows the closing price for APVO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aptevo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APVO

Analyst Price Target is $13.00
▲ +295.14% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Aptevo Therapeutics in the last 3 months. The average price target is $13.00, with a high forecast of $13.00 and a low forecast of $13.00. The average price target represents a 295.14% upside from the last price of $3.29.

This chart shows the closing price for APVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in Aptevo Therapeutics. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/12/2022Piper SandlerLower Target$20.00 ➝ $13.00Low
5/13/2022Piper SandlerLower Target$69.00 ➝ $20.00High
12/22/2021UBS GroupDowngradeBuy ➝ NeutralMedium
11/15/2021Roth CapitalLower TargetBuy$50.00 ➝ $36.00High
5/28/2021Roth CapitalLower TargetBuy$64.00 ➝ $50.00Low
11/11/2020Piper SandlerReiterated RatingOverweightLow
8/14/2020Piper SandlerBoost Target$24.00 ➝ $32.00High
5/15/2020Piper SandlerLower Target$24.00 ➝ $18.50Medium
3/4/2020Roth CapitalReiterated RatingBuyMedium
3/2/2020Piper SandlerLower Target$3.00 ➝ $1.70High
10/4/2019Piper Jaffray CompaniesLower Target$4.50 ➝ $3.00Low
5/23/2019Roth CapitalReiterated RatingBuyLow
4/15/2019Piper Jaffray CompaniesBoost TargetOverweight$4.00 ➝ $4.50Medium
3/13/2019Piper Jaffray CompaniesLower TargetOverweight$8.50 ➝ $4.00Low
11/15/2018Roth CapitalSet TargetBuy$12.00High
11/5/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$14.00Low
8/10/2018Piper Jaffray CompaniesReiterated RatingOverweight$11.00High
5/10/2018Piper Jaffray CompaniesBoost TargetOverweight$6.00 ➝ $9.00Low
4/11/2018Roth CapitalInitiated CoverageBuy$12.00High
(Data available from 12/7/2017 forward)

News Sentiment Rating

0.85 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
5/11/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/10/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/9/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/8/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/7/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2022

Current Sentiment

  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Aptevo Therapeutics logo
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $3.29
Low: $3.29
High: $3.29

50 Day Range

MA: $2.99
Low: $2.67
High: $3.35

52 Week Range

Now: $3.29
Low: $2.67
High: $9.10

Volume

30 shs

Average Volume

20,011 shs

Market Capitalization

$16.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

5.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Aptevo Therapeutics?

The following Wall Street research analysts have issued research reports on Aptevo Therapeutics in the last twelve months: Piper Sandler, StockNews.com, TheStreet, and UBS Group AG.
View the latest analyst ratings for APVO.

What is the current price target for Aptevo Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Aptevo Therapeutics in the last year. Their average twelve-month price target is $13.00, suggesting a possible upside of 295.1%. Piper Sandler has the highest price target set, predicting APVO will reach $13.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $13.00 for Aptevo Therapeutics in the next year.
View the latest price targets for APVO.

What is the current consensus analyst rating for Aptevo Therapeutics?

Aptevo Therapeutics currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in APVO, but not buy more shares or sell existing shares.
View the latest ratings for APVO.

What other companies compete with Aptevo Therapeutics?

How do I contact Aptevo Therapeutics' investor relations team?

Aptevo Therapeutics' physical mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company's listed phone number is (206) 838-0500 and its investor relations email address is [email protected] The official website for Aptevo Therapeutics is www.aptevotherapeutics.com. Learn More about contacing Aptevo Therapeutics investor relations.